BRISTOL-MYERS SQUIBB COMPANY OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2021-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2021-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2021-06-30 was -$1.00M, a 133.33% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for the quarter ending 2020-12-31 was -$1.00M, a 114.29% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2025 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2023 was $1.00M.
- BRISTOL-MYERS SQUIBB COMPANY oci, debt securities, available-for-sale, gain (loss), before adjustment, tax for fiscal 2022 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-11 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-11 | |||
| 2023-12-31 | $1.00M 10-K · filed 2026-02-11 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $0.00 derived: sum of 2 quarters · filed 2024-02-13 | -$1.00M derived: sum of 3 quarters · filed 2024-02-13 | -$2.00M 10-K · filed 2024-02-13 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | -$1.00M derived: sum of 2 quarters · filed 2021-10-27 | -$2.00M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | -$1.00M 10-Q · filed 2021-07-28 | -$2.00M 10-Q · filed 2021-07-28 | ||
| 2020-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$3.00M derived: sum of 2 quarters · filed 2023-02-14 | $0.00 derived: sum of 3 quarters · filed 2023-02-14 | $1.00M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $1.00M derived: sum of 2 quarters · filed 2021-10-27 | $2.00M 10-Q · filed 2021-10-27 | $9.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $3.00M 10-Q · filed 2021-07-28 | $4.00M 10-Q · filed 2021-07-28 | $11.00M derived: sum of 3 quarters · filed 2022-02-09 | $13.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $1.00M 10-Q · filed 2020-05-07 | $8.00M derived: sum of 2 quarters · filed 2022-02-09 | $10.00M derived: sum of 3 quarters · filed 2022-02-09 | $10.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2019-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $9.00M derived: sum of 2 quarters · filed 2022-02-09 | $9.00M derived: sum of 3 quarters · filed 2022-02-09 | $9.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.00M derived: sum of 2 quarters · filed 2020-11-05 | $2.00M 10-Q · filed 2020-11-05 | $2.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-02-10 | $2.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-02-10 | $2.00M derived: sum of 3 quarters · filed 2021-02-10 | $1.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | $2.00M derived: sum of 2 quarters · filed 2021-02-10 | $1.00M derived: sum of 3 quarters · filed 2021-02-10 | -$5.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $1.00M derived: sum of 2 quarters · filed 2019-10-31 | -$5.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | -$1.00M 10-Q · filed 2019-07-25 | -$7.00M 10-Q · filed 2019-07-25 | ||
| 2018-03-31 | -$6.00M 10-Q · filed 2019-04-25 | |||
| 2017-12-31 | -$6.00M 10-K · filed 2020-02-24 | |||
| 2016-12-31 | $1.00M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |